All Blogs
May 31, 2024
The Journey of PD-(L)1 Inhibitors: Milestones and Breakthroughs
The advent of PD-(L)1 inhibitors marks a monumental shift in the landscape of cancer treatment. These agents have redefined the therapeutic approach to several malignancies, offering hope where traditional therapies often fell short. PD-(L)1 inhibitors are a class of drugs that block the interaction between the pro...
Read More...
May 30, 2024
Solis Mammography’s Acquisition of MUSIC Imaging Center; Nikon’s SI-PH Phase Condenser Accessory Option; Teijin Launch Surgical Patch; Terumo Cardiovascular’s FDA 510(K) Clearance; Spineart’s 510(k) Clearance; Ceretrieve’s Success in FIH Ischemic Stroke Cases
Solis Mammography Announced Acquisition of MUSIC Imaging Center in Gainesville, Florida On May 28, 2024, Solis Mammography announced the acquisition of the MUSIC Mammography and Ultrasound Imaging Center in Gainesville, Florida. For more than 10 years, MUSIC has provided patients with an advanced standard ...
Read More...
May 29, 2024
From Lab to Lifesaver: Advancing Artificial Blood Vessels for Healthier Tomorrows
Artificial blood vessels are at the forefront of medical innovation, offering a lifeline to millions worldwide. With advancements in bioengineering, these synthetic conduits are shaping a new era in healthcare, promising solutions to cardiovascular diseases and beyond. Artificial blood vessels represent a revolu...
Read More...
May 28, 2024
AstraZeneca’s Tropion-Lung01 Phase III Trial Positive Outcomes; Biogen’s LEQEMBI South Korea Approval; AltruBio’s $225M Series B Funding; GSK’s Depemokimab Positive Phase III Severe Asthma Results; Roche’s Inavolisib FDA Breakthrough Therapy Designation
The Tropion-Lung01 Phase III Trial Reveals that Datopotamab Deruxtecan Significantly Enhanced Overall Survival in Advanced Nonsquamous NSCLC Patients Compared to Chemotherapy The high-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which had previously met the dual primary endpoint o...
Read More...
Mar 18, 2026
Emerging Therapies for Retinal Vein Occlusion Treatment: What Lies Ahead?
Retinal vein occlusion is the second most common retinal vascular disease after diabetic retinopathy and primarily affects people over 65, making aging a key driver of disease burden and of the growing retinal vascular occlusion market. RVO is broadly classified into central retinal vein occlusion (CRVO) and branch...
Read More...
Nov 08, 2024
Cervical Cancer Treatment: Navigating the Changing Landscape
Over the past two decades, the majority of countries in the 7MM have experienced a decrease in cervical cancer cases. In the United States, incidence rates declined from the mid-1970s to the mid-2000s, partly attributed to increased screening efforts. Cervical cancer is most often diagnosed between the age...
Read More...
May 23, 2024
Laborie’s Enhanced Gastrointestinal Diagnostics; Carestream’s Image Suite MR 10 Software Launch; Implicity’s Heart Failure Algorithm FDA 510(k) Approval; AngioDynamics’ AlphaVac F1885 System CE Mark Approval; HeartBeam’s Artificial Intelligence Algorithm for Arrhythmias; Onward ARC-EX Nerve Stim Hit Pivotal Trial
Laborie Launched Solar Compact System and Solar Anorectal Manometry Catheter for Enhanced Gastrointestinal Diagnostics On May 20, 2024, Laborie Medical Technologies Corp., launched the Solar Compact System and Solar Anorectal Manometry Catheter, the first disposable HRAM catheter on the market. These devices sig...
Read More...
May 22, 2024
The Evolution and Impact of Surgical Cameras in Modern Medicine
In the fast-paced and precision-driven world of modern medicine, surgical cameras have emerged as a transformative technology. Among the myriad of technological advancements, surgical cameras stand out as a transformative innovation. These devices have revolutionized the way surgeons perform operations, offering un...
Read More...
May 21, 2024
Amgen’s IMDELLTRA FDA Approval; J&J’s Proteologix Acquisition; Bristol Myers Squibb’s BREYANZI FDA Approval; AbbVie and Gilgamesh Pharmaceuticals’ Agreement; Eisai’s LEQEMBI FDA Fast Track Status
IMDELLTRA Receives FDA Approval as the First T-Cell Engager Therapy for Advanced Small Cell Lung Cancer Amgen has reported that the FDA has approved IMDELLTRA™ (tarlatamab-dlle) for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following pl...
Read More...
May 20, 2024
Atopic Dermatitis Treatment: Rich Portfolio of Therapeutic Options Shaping the Future
Atopic dermatitis is common worldwide, and people of all ages, from newborns to adults 65 and older, live with this condition. The World Health Organization (WHO) Global Burden of Diseases initiative estimates more than 230 million people globally have atopic dermatitis and that skin diseases are the fourth leading...
Read More...